Upon DNA damage, CHK1, the CHEK1 lncRNA-associated mRNA, enables cell cycle arrest and DNA damage repair; thus, its inhibition may confer therapeutic targeting of CSCs in many cancer types, including PDAC, colorectal cancer, prostate cancer, non-small-cell lung cancer, and acute myeloid leukemia [63,64,65,66,67,68]. Here, CHEK1 is linked to prostate cancer.